Therapeutic Class Report Overview - Rituxan Biosimilar

Category: Biopharmaceuticals
Industry: Healthcare

Over USD 60 billion worth of sales of biologics in the US/EU will lose patent protection between 2012 and 2017. Growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Out of them, Roches/Biogen Idecs Rituxan/MabThera (rituximab), Merck and JNJs Remicade (infliximab), Amgen and Pfizers Enbrel (etanercept) had sales of USD 23 bn in 2011 and have patents expiring in EU and ROW in 2013-2014.

The growth in the biosimilar opportunity will be driven by several patent expiries of mega-blockbuster biologics in the next 5 years. Between 2012 and 2017, over $60b worth of sales of biologics in the US/EU will lose patent protection. Out of them, Roches/Biogen Idecs Rituxan/MabThera (rituximab), Merck and JNJs Remicade (infliximab), and Amgen and Pfizers Enbrel (etanercept) had WW sales of $23b in 2011 and have patents expiring in EU and ROW in 2013/14. Biosimilar version of Rituxan was launched by Dr Reddys Lab. (DRL), Reditux, in India in 2007 and many others are in the pipeline targeting EU, ROW market; Roche is deploying life-cycle management strategies to protect its Rituximab franchise, which despite competition continues to have a healthy growth rate.

In this report, we have analyzed the market opportunity of Rituximab Biosimilar and its competitive landscape. We believe that despite several clinical setbacks in the Rituxan biosimilars pipeline, they could pose a challenge to Rituximab by 2018.

To order this report: http://www.researchonglobalmarkets.com/therapeutic-class-report-overview-rituxan-biosimilar.html

Email: [email protected]
US: +1 866 325 7446
UK: +44 203 514 2363
India: +91 22 4098 7600
SOURCE: Researchonglobalmarkets

RELATED LINKS:
http://marketresearchreports.edublogs.org